A Study of Brentuximab Vedotin (SGN-35) in CD30-Positive Systemic Mastocytosis With or Without an Associated Hematological Clonal Non-Mast Cell Lineage Disease (AHNMD)
Phase of Trial: Phase II
Latest Information Update: 04 Jul 2017
At a glance
- Drugs Brentuximab vedotin (Primary)
- Indications Leukaemia; Systemic mastocytosis
- Focus Therapeutic Use
- 27 Jun 2017 Planned End Date changed from 1 Jun 2017 to 1 Dec 2017.
- 27 Jun 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.
- 23 Nov 2015 Planned End Date changed from 1 Sep 2014 to 1 Jun 2017 as reported by ClinicalTrials.gov record.